Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:BCTNASDAQ:IPANASDAQ:PMNNASDAQ:TH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTBriaCell TherapeuticsC$10.60-3.8%C$10.60C$3.50▼C$15.75C$168.68MN/A12,671 shs3,402 shsIPAImmunoPrecise Antibodies$0.56+13.9%$0.44$0.27▼$1.18$25.50M-0.052.12 million shs897,708 shsPMNProMIS Neurosciences$0.51+0.0%$0.60$0.47▼$2.37$16.51M0.0275,954 shs13,840 shsTHTarget Hospitality$7.37-3.0%$6.73$4.00▼$11.57$732.31M1.89608,670 shs386,985 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTBriaCell Therapeutics0.00%0.00%0.00%0.00%0.00%IPAImmunoPrecise Antibodies+13.93%+12.59%+25.47%+44.29%-52.79%PMNProMIS Neurosciences-1.75%+1.00%-15.10%-38.04%-69.94%THTarget Hospitality-3.03%+3.80%+14.80%-21.26%-35.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTBriaCell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies2.2408 of 5 stars3.55.00.00.00.00.01.3PMNProMIS Neurosciences1.5948 of 5 stars3.52.00.00.01.10.80.6THTarget Hospitality2.6146 of 5 stars3.44.00.00.01.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTBriaCell Therapeutics 0.00N/AC$15.0041.51% UpsideIPAImmunoPrecise Antibodies 3.00Buy$4.00618.00% UpsidePMNProMIS Neurosciences 3.00Buy$4.50791.09% UpsideTHTarget Hospitality 2.75Moderate Buy$11.2552.65% UpsideCurrent Analyst Ratings BreakdownLatest PMN, BCT, IPA, and TH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025PMNProMIS NeurosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/11/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/1/2025IPAImmunoPrecise AntibodiesBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$3.00 ➝ $3.004/1/2025PMNProMIS NeurosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/31/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.003/31/2025THTarget HospitalityStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$5.00 ➝ $7.503/14/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.002/26/2025PMNProMIS NeurosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy2/26/2025THTarget HospitalityStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$10.00 ➝ $5.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTBriaCell TherapeuticsN/AN/AC$3.34 per share3.17C$3.60 per shareN/AIPAImmunoPrecise Antibodies$24.00M1.06N/AN/A$0.93 per share0.60PMNProMIS NeurosciencesN/AN/AN/AN/A$0.20 per shareN/ATHTarget Hospitality$386.27M1.90$1.87 per share3.94$3.71 per share1.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTBriaCell TherapeuticsN/A-C$0.38N/A∞N/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies-$20.13M-$1.16N/AN/AN/A-114.50%-73.74%-42.68%8/4/2025 (Estimated)PMNProMIS Neurosciences-$13.21M-$0.05N/AN/AN/AN/A-636.20%-130.32%N/ATHTarget Hospitality$173.70M$0.708.4720.471.8120.84%22.80%12.82%8/6/2025 (Estimated)Latest PMN, BCT, IPA, and TH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025THTarget Hospitality-$0.02-$0.05-$0.03-$0.07$65.37 million$69.90 million5/12/2025Q1 2025PMNProMIS Neurosciences-$0.14-$0.21-$0.07-$0.21N/AN/A3/31/2025Q4 2024PMNProMIS Neurosciences-$0.14-$0.02+$0.12-$0.02N/AN/A3/28/2025Q3 2025IPAImmunoPrecise Antibodies-$0.06-$0.06N/A-$0.46$6.59 million$4.23 million3/26/2025Q4 2024THTarget Hospitality$0.06$0.12+$0.06$0.12$80.10 million$83.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTBriaCell TherapeuticsN/AN/AN/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/ATHTarget HospitalityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTBriaCell Therapeutics0.05129.63128.68IPAImmunoPrecise Antibodies0.361.010.85PMNProMIS NeurosciencesN/A9.309.30THTarget HospitalityN/A1.011.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTBriaCell TherapeuticsN/AIPAImmunoPrecise Antibodies6.70%PMNProMIS Neurosciences50.13%THTarget Hospitality32.40%Insider OwnershipCompanyInsider OwnershipBCTBriaCell TherapeuticsN/AIPAImmunoPrecise Antibodies6.83%PMNProMIS Neurosciences6.11%THTarget Hospitality68.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTBriaCell Therapeutics515.91 millionN/ANot OptionableIPAImmunoPrecise Antibodies8045.77 million28.94 millionNot OptionablePMNProMIS Neurosciences532.69 million31.25 millionNot OptionableTHTarget Hospitality82099.36 million32.65 millionNot OptionablePMN, BCT, IPA, and TH HeadlinesRecent News About These CompaniesQ2 EPS Estimate for Target Hospitality Lowered by AnalystMay 24 at 7:37 AM | marketbeat.comAnalysts Offer Insights on Industrial Goods Companies: Target Hospitality (TH), Paccar (PCAR) and Carrier Global (CARR)May 22 at 3:53 AM | theglobeandmail.comTarget Hospitality Announces Seat on $4 Billion Multi-Year U.S. Government Strategic Sourcing VehicleMay 21 at 6:45 AM | prnewswire.comTarget Hospitality Corp. (NASDAQ:TH) Q1 2025 Earnings Call TranscriptMay 20, 2025 | insidermonkey.comTarget Hospitality Corp. (NASDAQ:TH) Q1 2025 Earnings Call TranscriptMay 20, 2025 | msn.comTarget Hospitality Corp. (TH) Q1 2025 Earnings Call TranscriptMay 19, 2025 | seekingalpha.comTarget Hospitality (NASDAQ:TH) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds ExpectationsMay 19, 2025 | msn.comTarget Hospitality (TH) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 19, 2025 | zacks.comTarget Hospitality (TH) Reports Q1 Loss, Tops Revenue EstimatesMay 19, 2025 | zacks.comTarget Hospitality Reports First Quarter 2025 Results with Continued Focus on Pursuing Strong Strategic Growth PipelineMay 19, 2025 | prnewswire.comDimensional Fund Advisors LP Acquires 161,036 Shares of Target Hospitality Corp. (NASDAQ:TH)May 17, 2025 | marketbeat.comInsights into Target Hospitality's Upcoming EarningsMay 16, 2025 | benzinga.comHere's What to Know Ahead of Target Hospitality's Q1 EarningsMay 15, 2025 | zacks.com1,012,000 Shares in Target Hospitality Corp. (NASDAQ:TH) Acquired by Empyrean Capital Partners LPMay 11, 2025 | marketbeat.comTarget Hospitality (TH) to Release Earnings on WednesdayMay 9, 2025 | marketbeat.comTarget Hospitality Corp. (NASDAQ:TH) Holdings Lifted by Conversant Capital LLCMay 9, 2025 | marketbeat.comTarget Hospitality Announces First Quarter 2025 Earnings Release and Conference Call ScheduleMay 9, 2025 | prnewswire.comTudor Investment Corp ET AL Acquires 87,895 Shares of Target Hospitality Corp. (NASDAQ:TH)May 7, 2025 | marketbeat.comTarget Hospitality to Participate in Oppenheimer 20th Annual Industrial Growth ConferenceMay 6, 2025 | prnewswire.comTarget Hospitality (NASDAQ:TH) Stock Price Up 5.5% - What's Next?May 1, 2025 | marketbeat.comTarget Hospitality (TH): Buy, Sell, or Hold Post Q4 Earnings?May 1, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Super Micro Computer Stock Clears New Path Higher on Saudi OrdersBy Gabriel Osorio-Mazilli | May 22, 2025View Super Micro Computer Stock Clears New Path Higher on Saudi Orders3 Mid-Cap Stocks Turning Heads in AI, Automation, & CybersecurityBy Nathan Reiff | May 16, 2025View 3 Mid-Cap Stocks Turning Heads in AI, Automation, & CybersecurityThe Top-Ranked Insider Buys From April by Market CapBy Thomas Hughes | May 6, 2025View The Top-Ranked Insider Buys From April by Market CapGoldman Sachs Warns of 20% Market Sell-Off: Are They Right?By Gabriel Osorio-Mazilli | May 13, 2025View Goldman Sachs Warns of 20% Market Sell-Off: Are They Right?PMN, BCT, IPA, and TH Company DescriptionsBriaCell Therapeutics CVE:BCTC$10.60 -0.42 (-3.81%) As of 12/30/2021BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.ImmunoPrecise Antibodies NASDAQ:IPA$0.56 +0.07 (+13.93%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.52 -0.04 (-7.02%) As of 05/23/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.ProMIS Neurosciences NASDAQ:PMN$0.52 +0.01 (+2.81%) As of 05/23/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Target Hospitality NASDAQ:TH$7.37 -0.23 (-3.03%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$7.37 0.00 (0.00%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Target Hospitality Corp. operates as a specialty rental and hospitality services company in North America. The company operates through two segments, Hospitality & Facilities Services - South and Government. It owns a network of specialty rental accommodation units. In addition, the company provides catering and food, maintenance, housekeeping, grounds-keeping, security, health and recreation facilities, workforce community management, concierge, and laundry services. It serves the U.S. government contractors and investment grade natural resource development companies. Target Hospitality Corp. was founded in 1978 and is headquartered in The Woodlands, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
